Validation of a blood-based autoantibody test to assess lung cancer risk in 4–30 mm pulmonary nodules: a retrospective pooled analysis of four cohort studies
AAT provides size- and risk-independent, high-specificity rule-in performance, identifying subsets of patients whose malignancy risk may justify expedited evaluation.
Authors
- Dragos Zanchi
- SANDEEP BANSAL
- Bharat Bajantri
- Luke Yuhico
- Laura J. Peek
- S Schuldheisz
- V. Nair
- Trevor J. Pitcher
- Kathryn J. Long
- James R. Jett
- Tammy Gleeson
- Gerard A. Silvestri
- Michael N. Kammer
Institutions
- Cleveland Clinic (US)
- Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa (ZA)
- Medical University of South Carolina (US)
- Université Toulouse-I-Capitole (FR)
- Fred Hutch Cancer Center (US)
- St. Francis Sleep, Allergy, and Lung Institute (US)
- Penn Highlands Healthcare (US)
- SouthCoast Health (US)
- The White House (US)
- Parkview Medical Center (US)
- Tampa Bay Research Institute (US)
- Parkview Mirro Center for Research and Innovation
Publication Details
- Journal
- Future Oncology
- Published
- 2026-02-17
- DOI
- https://doi.org/10.1080/14796694.2026.2626339
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00